WeTrials
Recruiting

A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases

What is this study?

This study tests a new experimental drug called AO-252 in adults with advanced solid tumors, including cancers that have spread to the brain. Researchers want to find out the safest dose and see how well the treatment works against these cancers.

Who can participate?

Adults aged 18 and older with advanced solid tumors that have returned or did not respond to prior treatments may be eligible. Participants must meet specific health guidelines, such as being able to swallow pills and not having certain active brain symptoms.

What will happen?

Participants will receive the study drug AO-252 while doctors closely monitor their safety, side effects, and overall health. The team will gradually find the best and safest dose for future studies.

Where and when?

This study is currently recruiting patients at locations in Detroit, Michigan, Oklahoma City, Oklahoma, and Charleston, South Carolina. Your care team can help you determine if one of these locations is right for you.

Key Points
  • 1Testing a new experimental drug called AO-252 for advanced solid tumors
  • 2Open to adults whose previous cancer treatments did not work or stopped working
  • 3Currently recruiting patients at multiple medical centers in the United States

Related video

AO-252: sponsor interview on TACC3 research and development (2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumor MalignanciesBrain Metastases From Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.